Filing Flows › Prelude Therapeutics (PRLD) › R&D spending
Prelude Therapeutics (PRLD) R&D spending by quarter
Prelude Therapeutics' R&D spending was $16.1M in Q2 2026 (second quarter 2026), +19% from Q1 2026. Over the last 5 quarters it ranged from $13.6M (Q1 2026) to $31.6M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $16.1M | +19% | — |
| Q1 2026 | $13.6M | -24% | — |
| Q4 2025 | $18.0M | -17% | -43% |
| Q3 2025 | $21.7M | -31% | — |
| Q4 2024 | $31.6M | — | — |
Q2 2026 at a glance
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Prelude Therapeutics' R&D spending?
Prelude Therapeutics' R&D spending was $16.1M in Q2 2026 (second quarter 2026), +19% from Q1 2026.
How has Prelude Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $13.6M (Q1 2026) to $31.6M (Q4 2024).